MedTrace Logo

Neuromodulation and Language Acquisition (Stage Ib)

NCT00102856 · Status: SUSPENDED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2010-06-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether rivastigmine or pramipexol are effective in boosting semantic language acquisition in healthy subjects.

Conditions

  • Healthy

Interventions

DRUG

Pramipexole

DRUG

Rivastigmine

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Caterina Breitenstein, PhD · Dept. of Neurology, University Hospital Muenster

  • Stefan Knecht, MD · Dept. of Neurology, University Hospital Muenster

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Completion
2006-06-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00102856 on ClinicalTrials.gov